Literature DB >> 29869547

175 Years of Progress in PTSD Therapeutics: Learning From the Past.

Murray B Stein1, Barbara O Rothbaum1.   

Abstract

Traumatic stressors have always been a part of the human experience. What is now referred to as posttraumatic stress disorder (PTSD) was first studied in the context of military trauma during the Civil War and World War I but most extensively in World War II. Much of what we know about the medical and psychological management of PTSD has its origins in military psychiatric approaches, and a review of these practices reveals important tenets that should be applied in current treatment for both military and nonmilitary PTSD. These practices include intervention as soon as possible after the traumatic exposure, provision for a safe and supportive therapeutic milieu designed for an individual's relatively rapid return to his or her responsibilities and normal activities, and using a combination of pharmacotherapy and psychotherapy (especially exposure to the traumatic memory). A review of current guidelines for treatment of PTSD reveals that few treatments are endorsed with great certainty, owing in large part to a paucity of clinical trials, particularly of pharmacotherapy. This shortcoming must be addressed to enable translation of promising discoveries in the neuroscience of fear into the therapeutic advances patients need and deserve. [AJP at 175: Remembering Our Past As We Envision Our Future March 1947: Psychiatric Experience in the War, 1941-1946 Brig. General William C. Menninger "Another observation which can be made as a result of our experience, is that if intensive treatment was provided early, in an environment in which the expectation of recovery prevailed, remarkable results were obtained." (Am J Psychiatry 1947; 103:577-586 )].

Entities:  

Keywords:  Exposure Therapy; Military Psychiatry; Posttraumatic Stress Disorder; Trauma; War

Mesh:

Substances:

Year:  2018        PMID: 29869547     DOI: 10.1176/appi.ajp.2017.17080955

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  7 in total

1.  The Range of Psychotherapies for PTSD.

Authors:  John C Markowitz
Journal:  Am J Psychiatry       Date:  2018-10-01       Impact factor: 18.112

Review 2.  Translating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders.

Authors:  Kerry J Ressler
Journal:  Am J Psychiatry       Date:  2020-03-01       Impact factor: 18.112

Review 3.  Role of the dorsal periaqueductal gray in posttraumatic stress disorder: mediation by dopamine and neurokinin.

Authors:  M L Brandão; T A Lovick
Journal:  Transl Psychiatry       Date:  2019-09-17       Impact factor: 6.222

4.  Towards precision medicine for stress disorders: diagnostic biomarkers and targeted drugs.

Authors:  H Le-Niculescu; K Roseberry; D F Levey; J Rogers; K Kosary; S Prabha; T Jones; S Judd; M A McCormick; A R Wessel; A Williams; P L Phalen; F Mamdani; A Sequeira; S M Kurian; A B Niculescu
Journal:  Mol Psychiatry       Date:  2019-03-12       Impact factor: 15.992

5.  Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population - a machine learning approach.

Authors:  Patrick Gagnon-Sanschagrin; Jeff Schein; Annette Urganus; Elizabeth Serra; Yawen Liang; Primrose Musingarimi; Martin Cloutier; Annie Guérin; Lori L Davis
Journal:  BMC Psychiatry       Date:  2022-09-29       Impact factor: 4.144

6.  Genome-wide translational profiling of amygdala Crh-expressing neurons reveals role for CREB in fear extinction learning.

Authors:  Kenneth M McCullough; Chris Chatzinakos; Jakob Hartmann; Galen Missig; Rachael L Neve; Robert J Fenster; William A Carlezon; Nikolaos P Daskalakis; Kerry J Ressler
Journal:  Nat Commun       Date:  2020-10-14       Impact factor: 14.919

7.  Insulin-like growth factor I mitigates post-traumatic stress by inhibiting AMP-kinase in orexin neurons.

Authors:  M Estrella Fernández de Sevilla; Jaime Pignatelli; Jonathan A Zegarra-Valdivia; Pablo Mendez; Angel Nuñez; Ignacio Torres Alemán
Journal:  Mol Psychiatry       Date:  2022-02-03       Impact factor: 13.437

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.